UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

Stock Information for Revance Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Revance Therapeutics Inc.

Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp
Court Denies Renovaro Motion for an Expedited Trial in July
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition
Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: AI-Driven Biomarker and Drug Discovery for Precision Health"
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
Predictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned Drugs
Renovaro Provides Update to Definitive Agreement with Predictive Oncology

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.